Evogene (TA:EVGN) — Stock Price
Evogene (TA:EVGN) is currently trading at ILA226.90 ILA, up 12.10% today. Over the past 52 weeks, shares have ranged between ILA118.50 and ILA461.00. This page tracks Evogene's live share price on the TA exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see EVGN stock market capitalisation.
Evogene (EVGN) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Evogene's daily closing share price and trading volume on the TA exchange over the past year, giving a clear view of recent price momentum and liquidity.
Evogene Income Statement — Revenue, Profit & Earnings by Year
Evogene's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | ILA8.51 Million | ILA5.64 Million | ILA1.68 Million | ILA930.00K | ILA1.04 Million |
| Cost of Revenue | ILA2.68 Million | ILA1.69 Million | ILA909.00K | ILA767.00K | ILA574.00K |
| Gross Profit | ILA5.83 Million | ILA3.95 Million | ILA766.00K | ILA163.00K | ILA466.00K |
| Research & Development | ILA16.65 Million | ILA20.78 Million | ILA20.79 Million | ILA23.86 Million | ILA19.96 Million |
| SG&A | ILA10.04 Million | ILA6.07 Million | ILA6.48 Million | ILA9.34 Million | ILA7.47 Million |
| Total Operating Expenses | ILA28.04 Million | ILA30.46 Million | ILA27.71 Million | ILA31.12 Million | ILA25.28 Million |
| Operating Income | ILA-22.21 Million | ILA-26.51 Million | ILA-26.94 Million | ILA-30.95 Million | ILA-24.81 Million |
| EBITDA | ILA-15.48 Million | ILA-23.26 Million | ILA-27.01 Million | ILA-27.88 Million | ILA-23.21 Million |
| EBIT | ILA-17.98 Million | ILA-25.87 Million | ILA-29.59 Million | ILA-30.12 Million | ILA-25.94 Million |
| Interest Expense | ILA63.00K | ILA115.00K | ILA3.33 Million | ILA1.41 Million | ILA2.95 Million |
| Income Before Tax | ILA-18.05 Million | ILA-25.99 Million | ILA-29.75 Million | ILA-30.43 Million | ILA-26.17 Million |
| Income Tax Expense | ILA9.00K | ILA-33.00K | ILA90.00K | ILA13.00K | ILA32.00K |
| Net Income | ILA-16.48 Million | ILA-23.88 Million | ILA-29.84 Million | ILA-30.45 Million | ILA-26.21 Million |
Evogene Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Evogene's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | ILA39.86 Million | ILA51.10 Million | ILA56.13 Million | ILA76.30 Million | ILA71.92 Million |
| Total Current Assets | ILA21.59 Million | ILA34.47 Million | ILA37.75 Million | ILA56.89 Million | ILA51.82 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | ILA10.00K | ILA10.29 Million | ILA6.38 Million | ILA21.54 Million | ILA2.00 Million |
| Net Receivables | ILA1.49 Million | ILA804.00K | ILA803.00K | ILA1.17 Million | ILA2.24 Million |
| Inventory | ILA1.82 Million | ILA76.00K | ILA566.00K | ILA92.00K | ILA0.00 |
| Property, Plant & Equipment | — | — | ILA4.07 Million | ILA4.18 Million | ILA3.94 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | ILA25.03 Million | ILA22.42 Million | ILA21.34 Million | ILA12.88 Million | ILA15.03 Million |
| Total Current Liabilities | ILA18.70 Million | ILA6.94 Million | ILA5.62 Million | ILA6.88 Million | ILA9.68 Million |
| Long-term Debt | — | ILA10.37 Million | ILA10.11 Million | — | — |
| Net Debt | ILA-2.43 Million | ILA-9.27 Million | ILA-17.05 Million | ILA-29.66 Million | ILA-43.79 Million |
| Total Stockholder Equity | ILA-1.45 Million | ILA12.05 Million | ILA27.93 Million | ILA54.03 Million | ILA46.05 Million |
| Retained Earnings | ILA-274.07 Million | ILA-257.59 Million | ILA-233.71 Million | ILA-207.07 Million | ILA-179.28 Million |
Evogene Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Evogene generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | ILA-19.70 Million | ILA-21.58 Million | ILA-23.68 Million | ILA-24.84 Million | ILA-19.51 Million |
| Capital Expenditures | ILA626.00K | ILA785.00K | ILA1.17 Million | ILA724.00K | ILA682.00K |
| Free Cash Flow | ILA-20.33 Million | ILA-22.36 Million | ILA-24.85 Million | ILA-25.56 Million | ILA-20.20 Million |
| Investing Cash Flow | ILA9.62 Million | ILA-4.54 Million | ILA13.27 Million | ILA-20.44 Million | ILA9.41 Million |
| Financing Cash Flow | ILA4.66 Million | ILA18.15 Million | ILA9.34 Million | ILA30.28 Million | ILA20.37 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | ILA1.79 Million | ILA1.88 Million | ILA1.19 Million | ILA2.61 Million | ILA4.10 Million |
| Depreciation | ILA2.50 Million | ILA2.61 Million | ILA2.58 Million | ILA2.23 Million | ILA2.73 Million |
| Change in Cash | ILA-5.47 Million | ILA-8.21 Million | ILA-3.35 Million | ILA-13.90 Million | ILA11.48 Million |
Evogene Earnings History — EPS Actual vs. Analyst Estimates
Track Evogene's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 19, 2026 | — | — | — |
| Mar 05, 2026 | — | -0.26 | — |
| Nov 20, 2025 | — | -0.41 | — |
| Aug 21, 2025 | — | -0.63 | — |
| May 21, 2025 | — | -0.09 | — |
| Mar 05, 2025 | — | — | — |
| Nov 21, 2024 | -1.31 | -1.17 | -11.97% |
| Aug 22, 2024 | -1.06 | -1.30 | +18.46% |